[HTML][HTML] Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
E Ku, L Del Vecchio, KU Eckardt, VH Haase… - Kidney international, 2023 - Elsevier
Anemia is common in patients with chronic kidney disease and is associated with a high
burden of morbidity and adverse clinical outcomes. In 2012, Kidney Disease: Improving …
burden of morbidity and adverse clinical outcomes. In 2012, Kidney Disease: Improving …
Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors
M Sugahara, T Tanaka, M Nangaku - Pharmacology & Therapeutics, 2022 - Elsevier
For the past 3 decades, erythropoiesis-stimulating agents (ESA) in conjunction with iron
supplementation has been the mainstay of treatment for anemia in chronic kidney disease …
supplementation has been the mainstay of treatment for anemia in chronic kidney disease …
[HTML][HTML] Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference
In chronic kidney disease, anemia and disordered iron homeostasis are prevalent and
associated with significant adverse consequences. In 2012, Kidney Disease: Improving …
associated with significant adverse consequences. In 2012, Kidney Disease: Improving …
Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES)
J Barratt, B Andric, A Tataradze… - Nephrology Dialysis …, 2021 - academic.oup.com
Background Roxadustat, an orally administered hypoxia-inducible factor prolyl hydroxylase
inhibitor, is being evaluated for treatment of anaemia of chronic kidney disease (CKD) …
inhibitor, is being evaluated for treatment of anaemia of chronic kidney disease (CKD) …
Managing anemia across the stages of kidney disease in those hyporesponsive to erythropoiesis-stimulating agents
MR Weir - American Journal of Nephrology, 2021 - karger.com
Background: Patients with CKD frequently have anemia that results from iron-restricted
erythropoiesis and inflammation. Anemia of CKD is currently managed with iron …
erythropoiesis and inflammation. Anemia of CKD is currently managed with iron …
[HTML][HTML] Efficacy and cardiovascular safety of roxadustat in dialysis-dependent chronic kidney disease: pooled analysis of four phase 3 studies
J Barratt, W Sulowicz, M Schömig, C Esposito… - Advances in …, 2021 - Springer
Introduction This integrated phase 3 analysis examined efficacy and cardiovascular safety
for roxadustat vs erythropoiesis-stimulating agents (ESAs) in dialysis-dependent patients …
for roxadustat vs erythropoiesis-stimulating agents (ESAs) in dialysis-dependent patients …
[HTML][HTML] Efficacy and cardiovascular safety of roxadustat for treatment of anemia in patients with non–dialysis-dependent CKD: Pooled results of three randomized …
R Provenzano, L Szczech, R Leong… - Clinical journal of the …, 2021 - journals.lww.com
Results A total of 4277 patients with non–dialysis-dependent CKD were randomized
(roxadustat, n= 2391; placebo, n= 1886). Baseline characteristics were comparable between …
(roxadustat, n= 2391; placebo, n= 1886). Baseline characteristics were comparable between …
[HTML][HTML] Evolving strategies in the treatment of anaemia in chronic kidney disease: the HIF-prolyl hydroxylase inhibitors
F Locatelli, R Minutolo, L De Nicola, L Del Vecchio - Drugs, 2022 - Springer
Chronic kidney disease (CKD) affects approximately 10% of the worldwide population;
anaemia is a frequent complication. Inadequate erythropoietin production and absolute or …
anaemia is a frequent complication. Inadequate erythropoietin production and absolute or …
Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: open‐label, dose‐selection, lead‐in stage of a phase 3 study
DH Henry, J Glaspy, R Harrup… - American journal of …, 2022 - Wiley Online Library
Anemia is the predominant cytopenia in myelodysplastic syndromes (MDS) and treatment
options are limited. Roxadustat is a hypoxia‐inducible factor prolyl hydroxylase inhibitor …
options are limited. Roxadustat is a hypoxia‐inducible factor prolyl hydroxylase inhibitor …
[HTML][HTML] Hypoxia-inducible factor prolyl hydroxylase inhibitors and iron metabolism
C Ogawa, K Tsuchiya, K Maeda - International Journal of Molecular …, 2023 - mdpi.com
The production of erythropoietin (EPO), the main regulator of erythroid differentiation, is
regulated by hypoxia-inducible factor (HIF). HIF2α seems to be the principal regulator of …
regulated by hypoxia-inducible factor (HIF). HIF2α seems to be the principal regulator of …